The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

European Archives of Psychiatry and Clinical Neuroscience

Volumn 254, Issue 6, 2004, Pages 356-361

  Mari, Jair De Jesus ^a   Lima, Mauricio S ^b   Costa, Anna Niccolai ^a   Alexandrino, Neusa ^c   Rodrigues Filho, Salomao ^d   De Oliveira, Irismar Reis ^e   Tollefson, Gary D ^f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^c Hospital Anna Rech   (Brazil)

^d Pax Clinica Psiquiatrica in Goiania   (Brazil)

^e FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^f Lilly Research Laboratories   (Brazil)

Author keywords

Olanzapine; Randomized controlled trial; Schizophrenia; Tardive dyskinesia; Typical antipsychotic

Indexed keywords

CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; OUTPATIENT CARE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEMOGRAPHY; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 13244256800     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-004-0514-1     Document Type: Article

References (22)

1. Beasley CM, Hamilton S, Crawford AM, et al. (1997) Olanzapine versus Haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125-137
2. Beasley CM, Dellva MA, Tamura RN, et al. (1999) Randomized double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br J Psychiatry 174:23-30
3. Bymaster FP, Calligaro DO, Falcone JF, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2):87-96
4. Duggan L, Fenton M, Dardennes RM, et al. (2003) Olanzapine for schizophrenia. Cochrane Database Syst Rev (1):CD001359
5. Glazer WM, Morgenstern H, Doucette JT (1993) Predicting the long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 54:133-139
6. Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15-20
7. Guy W (1976) Psychopharmacology Research Branch, NIMH. Abnormal Involuntary Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No (ADM) 76-338. Rockville, MD: National Institute of Mental Health, pp 534-537
8. Hotopf M, Churchill R, Lewis G (1999) Pragmatic randomized controlled trials in psychiatry. Br J Psychiatry 175:217-223
9. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D-2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369
10. Kapur S, Remington G (2001) Dopamine D-2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol Psychiatry 50(11):873-883
11. Kay SR, Opler LA, Fizbein A (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, New York, Multi Health Systems, Inc
12. Leitão R, Ferraz MB, Mari JJ (2002) A prevalence based cost of illness study of schizophrenia in São Paulo State, Brazil. Schizophr Res 53(Suppl 3):259
13. Lingjaerde O, Ahlfors UG, Bech P, et al. (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76(Suppl 334):1-100
14. Llorca PM, Chereeau I, Bayle F, et al. (2002) Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17:129-138
15. Loza N, El-Dosoky AM, Okasha TA, et al. (1999) Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol 9(Suppl 5):291
16. Mitchell IJ, Cooper AC, Griffiths MR, et al. (2002) Acute administration of haloperidol induces apoptosis of neuron in the striaturn and substantia nigra in the rat. Neuroscience 109(1):89-99
17. Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among chronic outpatients maintained on neuroleptic medications: results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 50:723-733
18. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 39:486-487
19. Seeman P, Tallerico T (1998) Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3(2):123-134
20. Seeman P (2002) Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47(1):27-38
21. Tollefson GD, Beasley CM, Tran PV, et al. (1997a) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154(4):457-465
22. Tollefson GD, Beasley CM, Tamura RN et al. (1997b) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154(9):1248-1254